自己免疫性肝炎の第一線治療として,ミコフェノラートモフェチルとアザチオプリン:比較的な体系的レビューとメタ解析
Amani M Ali1, Mohamed E Abdelrahim2, Aya M AbdelMagid3
1Clinical Pharmacy Department, Faculty of Pharmacy, Cairo University, P.O. Box: 11562, Giza, Egypt. amany.mohamed@pharma.cu.edu.eg.
BMC gastroenterology
|August 22, 2025
まとめ
ミコフェノラートモフェチル (MMF) は,アザチオプリン (AZA) よりも,自己免疫性肝炎 (AIH) の第一線治療として,より効果的で安全です. MMFはより高い寛解率とより少ない重篤な有害事象をもたらし,患者のアウトカムを改善します.
科学分野:
- ヘパトロジー
- 免疫学
- 薬理学について
背景:
- 自己免疫性肝炎 (AIH) は,免疫媒介による炎症と損傷によって特徴づけられる慢性肝疾患です.
- 標準的な治療はアザチオプリン (AZA) とステロイドですが,反応しない患者には代替薬が求められます.
研究 の 目的:
- ミコフェノラートモフェチル (MMF) とAZAをAIHの第一線療法として比較する.
- 寛解率や有害事象を含む治療結果を評価する.
主な方法:
- 治療前のAIH患者におけるMMFとAZAを比較した研究を体系的にレビューした.
- 完全生化学寛解 (CBR),無反応,再発率によって評価された有効性.
- 治療中止に至る重大な有害事象の発生率で評価される安全性
主要な成果:
- 512人の患者を含む4つの研究が分析されました.
- AZAと比較して,MMFは短期 (OR2. 56) と長期 (OR5. 51) のCBRを大幅に改善しました.
- MMF治療では重篤な有害事象の発生率が著しく低下した (OR0. 15).
結論:
- AIHに対するMMFベースの第一線治療は,AZAベースの治療法よりも有望です.
- MMFは優れた有効性を示し,より高いCBR率を達成しました.
- 治療中止が必要となる重篤な有害事象が少なく,安全性が向上します.
関連する概念動画
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
267
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
267
01:29Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
231
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
231
01:29Inflammatory Bowel Disease IV: Pharmacological Management
189
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
189
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
202
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
202